Clinical Observation of Letrozole in Preventing Ovarian Hyperstimulation Syndrome After Oocyte Retrieval
Objective To explore the value of letrozole(LE)in preventing ovarian hyperstimulation syndrome(OHSS)after oocyte retrieval.Methods A total of 300 patients were selected for this study from the Department of Reproductive Genetics at Zhengzhou Maternal and Child Health Hospital between May 2022 and March 2024.All patients underwent in vitro fertilization and embryo transfer(IVF-ET)treatment,employing a long protocol for controlled ovarian stimulation due to the high risk of OHSS,requiring full embryo cryopreservation.Based on the treatment regimen,patients were divided into two groups:the experimental group(n=150)received oral LE at a dose of 7.5 mg daily for 4 days starting from the day of oocyte retrieval,while the control group(n=150)did not receive LE.A prospective study design was used for follow-up and assessment of patients after oocyte retrieval,comparing estradiol(E2),complete blood count,liver and kidney function,coagulation function levels,bilateral ovarian size,abdominal and chest effusion,and the incidence of OHSS on the 3rd and 5th days post-retrieval.Results There were no statistically significant differences in clinical indicators between the two groups before oocyte retrieval(P＞0.05).On the 3rd and 5th days post-retrieval,E2 levels and white blood cell counts in the experimental group were significantly lower than those in the control group the difference was statistically significant(P＜0.05).No significant differences were found between the two groups regarding liver and kidney function and coagulation function indicators on the 3rd and 5th days post-retrieval(P＞0.05).Additionally,ultrasound measurements(maximum ovarian diameter and abdominal/chest effusion)on the 3rd and 5th days post-retrieval were significantly lower in the experimental group than those in the control group(P＜0.05).The incidence of OHSS in the experimental group was also significantly lower than that in the control group after treatment(P＜0.05).Conclusion The application of letrozole after oocyte retrieval for the prevention of OHSS can significantly improve clinical recovery indicators,alleviate bilateral ovarian enlargement and abdominal/chest effusion,and reduce the incidence of OHSS.Its overall application value is favorable,demonstrating significant clinical relevance.
国家科技期刊平台
NSTL
万方数据
